These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28192529)

  • 21. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
    Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.
    Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A;
    BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
    Violari A; Lindsey JC; Hughes MD; Mujuru HA; Barlow-Mosha L; Kamthunzi P; Chi BH; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P
    N Engl J Med; 2012 Jun; 366(25):2380-9. PubMed ID: 22716976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.
    Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T
    Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz is associated with higher bone mass in South African children with HIV.
    Arpadi SM; Shiau S; Strehlau R; Patel F; Mbete N; McMahon DJ; Kaufman JJ; Coovadia A; Kuhn L; Yin MT
    AIDS; 2016 Oct; 30(16):2459-2467. PubMed ID: 27427876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
    Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ
    J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
    Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
    Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
    AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
    Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
    Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS.
    Renner LA; Dicko F; Kouéta F; Malateste K; Gueye RD; Aka E; Eboua TK; Azondékon A; Okomo U; Touré P; Ekouévi D; Leroy V;
    J Int AIDS Soc; 2013 Sep; 16(1):18024. PubMed ID: 24047928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
    Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
    J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.